Assessment of Central Nervous System Responses in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Brexucabtagene Autoleucel As an FDA-Approved Standard of Care

The central nervous system (CNS) respresents a common site of extramedullary disease relapse in acute lymphoblastic leukmeia (ALL). CNS relapses contribute to adverse outcomes, and frequently exclude patients from participating in clinical trials. Current approved novel salvage therapies (bliantumomab and inotuzumab) have limited activity in B-ALL with CNS relapse. Brexucabtagene autoleucel (brexu-cel) was the first FDA-approved CAR T-cell product for adult patients with relapsed/refractory (r/r) B-ALL based on the ZUMA-3 study, which excluded patients with clincally evident CNS involvement.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Ibrahim N. Muhsen, Gregory Roloff, Noam E. Kopmar, Santiago Mercadal, Timothy E O'Connor, Kaitlyn C Dykes, Mohamed Ahmed, Simone E. Dekker, Nikeshan Jeyakumar, Muthu Veeraputhiran, Akash Mukherjee, Aaron C. Logan, Dr. Stephanie B. Tsai, Jessica T. Leonard Tags: 9 Source Type: research